bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy
Authors: Ghio Stefano , Pica Silvia , Klersy Catherine , Guzzafame Eleonora , Scelsi Laura , Raineri Claudia , Turco Annalisa , Schirinzi Sandra , Visconti Luigi Oltrona 
Published: May 2016

ObjectiveTo evaluate the prognostic significance of right ventricular function assessed by echocardiography after start or escalation of targeted therapy in patients with pulmonary arterial hypertension.MethodsStudy design: longitudinal study. Setting: tertiary referral centre for pulmonary hypertension. Patients: 81 consecutive patients with pulmonary arterial hypertension (33 naive and 48 prevalent). Interventions: right heart catheterisation and echocardiography performed prior to starting or escalating targeted therapy and repeated in 55 patients after 4–12 months of therapy. Main outcome measure: survival after follow-up examinations.Results11 patients died and 7 were lost to follow-up during the first year; 8 patients underwent first follow-up evaluation beyond 1 year. 55 patients were re-evaluated after therapy; during the subsequent follow-up period of 25 months, 9 patients died, 7 worsened from WHO I/II to III/IV and 15 remained in WHO III/IV despite therapy. A baseline tricuspid annular plane systolic excursion (TAPSE) ≥15 mm was associated with a lower risk of death (HR=0.32; 95% CI 0.12 to 0.83, p=0.012). Attaining a TAPSE≥15 mm after therapy was associated with a significantly lower risk of death or clinical worsening (HR=0.2; 95% CI 0.1 to 0.6, p=0.002) and a lower risk of death which approached statistical significance (HR=0.3; 95% CI 0.2 to 1.1, p=0.075). Per cent changes in TAPSE were loosely related to changes in pulmonary vascular resistances after therapy (R=0.37).ConclusionsIn patients with pulmonary arterial hypertension, the evaluation of right ventricular function by TAPSE after targeted therapy is useful to predict subsequent prognosis, regardless of the haemodynamic effects of therapy.
FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer
Authors: Weng Wenhao , Okugawa Yoshinaga , Toden Shusuke , Toiyama Yuji , Kusunoki Masato , Goel Ajay 
Published: May 2016

AbstractPurpose: Colorectal cancer ranks as the third most frequent cancer type, and its incidence continues to rise gradually worldwide, highlighting the need to identify previously unrecognized molecular events that propel development of this malignancy. Recent evidence suggests that dysregulated expression of FOX family of transcription factors may be critical in various genetic disorders as well as cancer; however, the functional and clinical significance of this pathway in colorectal cancer remains unclear.Experimental Design and Results: Herein, we performed a systematic and comprehensive discovery step by evaluating the expression of FOX family members, and identified that FOXM1 and FOXQ1 are frequently overexpressed in colorectal cancer. We subsequently confirmed these findings in two large testing cohorts (n = 550) and an independent clinical validation cohort (n = 134), in which high expression of FOXM1 and FOXQ1 emerged as an independent prognostic factor in colorectal cancer patients. We corroborated these findings by performing functional assays in which knockdown of FOXM1 and FOXQ1 resulted in inhibited cell proliferation and suppressed migration and invasion in colorectal cancer cells. Furthermore, using bioinformatic approaches, we identified miR-342 as a novel regulator of both FOXM1 and FOXQ1. Overexpression or inhibition of miR-342 modulated the expression of both genes and contributed to phenotypic alterations in colorectal cancer cells, which was subsequently validated in a xenograft animal model.Conclusions: Collectively, we have firstly identified FOXM1 and FOXQ1 as promising prognostic biomarkers in colorectal cancer patients, and provided novel evidence that therapeutic targeting of these genes or miR-342 may be a potential treatment approach in colorectal cancer patients. Clin Cancer Res; 22(19); 4947–57. ©2016 AACR.
Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions
Authors: Kashyap Abhishek S. , Shooter Gary K. , Shokoohmand Ali , McGovern Jacqui , Sivaramakrishnan Manaswini , Croll Tristan I. , Cane Gaëlle , Leavesley David I. , Söderberg Ola , Upton Zee , Hollier Brett G. 
Published: May 2016

AbstractWe provide proof-of-concept evidence for a new class of therapeutics that target growth factor:extracellular matrix (GF:ECM) interactions for the management of breast cancer. Insulin-like growth factor-I (IGF-I) forms multiprotein complexes with IGF-binding proteins (IGFBP) and the ECM protein vitronectin (VN), and stimulates the survival, migration and invasion of breast cancer cells. For the first time we provide physical evidence for IGFBP-3:VN interactions in breast cancer patient tissues; these interactions were predominantly localized to tumor cell clusters and in stroma surrounding tumor cells. We show that disruption of IGF-I:IGFBP:VN complexes with L27-IGF-II inhibits IGF-I:IGFBP:VN-stimulated breast cancer cell migration and proliferation in two- and three-dimensional assay systems. Peptide arrays screened to identify regions critical for the IGFBP-3/-5:VN and IGF-II:VN interactions demonstrated IGFBP-3/-5 and IGF-II binds VN through the hemopexin-2 domain, and VN binds IGFBP-3 at residues not involved in the binding of IGF-I to IGFBP-3. IGFBP-interacting VN peptides identified from these peptide arrays disrupted the IGF-I:IGFBP:VN complex, impeded the growth of primary tumor-like spheroids and, more importantly, inhibited the invasion of metastatic breast cancer cells in 3D assay systems. These studies provide first-in-field evidence for the utility of small peptides in antagonizing GF:ECM-mediated biologic functions and present data demonstrating the potential of these peptide antagonists as novel therapeutics. Mol Cancer Ther; 15(7); 1602–13. ©2016 AACR.
ЕФЕКТИВНІСТЬ КОМПЛЕКСНОГО ЛІКУВАННЯ ХВОРИХ З ПОПЕРЕКОВИМ ОСТЕОХОНДРОЗОМ ЗА ДИНАМІКОЮ СТАНУ ЕНДОТЕЛІАЛЬНОЇ ДИСФУНКЦІЇ
Authors: Babinets L. S. , Nadkevych A. L. , Hotʹ I. V. 
Published: May 2016

<p>На сьогодні не вирішені численні питання етіопатогенезу, діагностики та лікування поперекового остеохондрозу (ПОХ). Зокрема, роль системи оксиду азоту (NO) у розвитку і прогресуванні ПОХ та остеодефіциту (ОД) залишається недостатньо з’ясованою.</p>
ПОКАЗНИКИ ОКИСНОГО ГОМЕОСТАЗУ ТА ВМІСТ ОКСИДУ АЗОТУ КРОВІ У ХВОРИХ НА ГІПЕРТОНІЧНУ ХВОРОБУ В ПОЄДНАННІ З ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ І ЦУКРОВИМ ДІАБЕТОМ ТИПУ 2
Authors: Boyko V. V. 
Published: May 2016

<p>Метою дослідження було вивчити стан оксидантно-антиоксидантної системи, вміст кінцевих продуктів монооксиду нітрогену (NO) крові у хворих на гіпертонічну хворобу (ГХ) ІІ стадії та в поєднанні з ішемічною хворобою серця (ІХС) і цукровим діабетом (ЦД) типу 2.</p>
КЛІНІЧНІ ПРОЯВИ ВЕГЕТАТИВНОГО ДИСБАЛАНСУ У КЛІМАКТЕРИЧНОМУ ПЕРІОДІ ТА МОЖЛИВОСТІ ЇХ КОРЕКЦІЇ
Authors: Zhdan V. M. , Katerenchuk I. P. 
Published: May 2016

<p>Актуальність проблеми. Вегетативні порушення, які виявляють майже у 80 % жінок, є найбільш ранніми проявами клімактеричного синдрому.<br />Кардіальна і церебральна симптоматика значно погіршує якість життя і є передумовою тяжких ускладнень, які погіршують якість життя<br />та зменшують його тривалість.</p>
Вплив захворювань щитоподібної залози на стоматологічний статус людини (огляд літератури)
Authors: Chorniy A. V. , Shmanko V. V. 
Published: May 2016

<p>The article adduces the problem of influence of thyroid disease on dental human health. Attention is paid to spread and character of pathological processes in periodontal prevalence of caries and non-carious lesions in patients with thyroid dysfunction. <strong></strong></p>
Enhanced Radiofrequency Ablation With Magnetically Directed Metallic Nanoparticles
Authors: Nguyen Duy T. , Tzou Wendy S. , Zheng Lijun , Barham Waseem , Schuller Joseph L. , Shillinglaw Benjamin , Quaife Robert A. , Sauer William H. 
Published: May 2016

Background—
Remote heating of metal located near a radiofrequency ablation source has been previously demonstrated. Therefore, ablation of cardiac tissue treated with metallic nanoparticles may improve local radiofrequency heating and lead to larger ablation lesions. We sought to evaluate the effect of magnetic nanoparticles on tissue sensitivity to radiofrequency energy.

Methods and Results—
Ablation was performed using an ablation catheter positioned with 10 g of force over prepared ex vivo specimens. Tissue temperatures were measured and lesion volumes were acquired. An in vivo porcine thigh model was used to study systemically delivered magnetically guided iron oxide (FeO) nanoparticles during radiofrequency application. Magnetic resonance imaging and histological staining of ablated tissue were subsequently performed as a part of ablation lesion analysis. Ablation of ex vivo myocardial tissue treated with metallic nanoparticles resulted in significantly larger lesions with greater impedance changes and evidence of increased thermal conductivity within the tissue. Magnet-guided localization of FeO nanoparticles within porcine thigh preps was demonstrated by magnetic resonance imaging and iron staining. Irrigated ablation in the regions with greater FeO, after FeO infusion and magnetic guidance, created larger lesions without a greater incidence of steam pops.

Conclusions—
Metal nanoparticle infiltration resulted in significantly larger ablation lesions with altered electric and thermal conductivity. In vivo magnetic guidance of FeO nanoparticles allowed for facilitated radiofrequency ablation without direct infiltration into the targeted tissue. Further research is needed to assess the clinical applicability of this ablation strategy using metallic nanoparticles for the treatment of cardiac arrhythmias.
Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure
Authors: Campbell Ross T. , Willox Gage P. , Jhund Pardeep S. , Hawkins Nathaniel M. , Huang Flora , Petrie Mark C. , McMurray John J.V. 
Published: May 2016

Background—
Premature treatment discontinuation and loss to follow-up (LTFU) with unknown outcomes leave uncertainty about the true efficacy and safety of a treatment and a lack of confidence in the results of any trial. We reviewed the extent of (and trends over time in) reporting LTFU and treatment discontinuation in large studies in chronic heart failure published since 1990.

Methods and Results—
Online databases were systematically reviewed to identify randomized controlled clinical trials (RCTs) in chronic heart failure with >400 participants and utilizing all-cause mortality as a component of the primary or secondary end point. Assessments were made of documentation of treatment discontinuation, LTFU, inclusion of and completeness of a Consolidated Standards Of Reporting Trials (CONSORT) diagram, and whether LTFU was differentiated from withdrawal of consent. Sixty-eight trials were identified, with >154 000 participants. Reasons for treatment discontinuation in pharmacotherapy trials were infrequently reported (35%), particularly in a CONSORT diagram (20%). Eighty-three percent of trials reported LTFU, although only 34% of these differentiated LTFU for vital status from withdrawal of consent. Use of a CONSORT diagram increased over time, although reporting of LTFU in the CONSORT diagram remained low overall at 35%.

Conclusions—
Participant flow through RCTs in chronic heart failure has not been uniformly reported, and the use of a complete CONSORT diagram has been low, although it seems to be improving. All study participants should be accounted for within a CONSORT diagram in any RCT to enable the practicing cardiologist to interpret how the results should influence his/her clinical practice.
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis
Authors: Popma Christopher J. , Sheng Shi , Korjian Serge , Daaboul Yazan , Chi Gerald , Tricoci Pierluigi , Huang Zhen , Moliterno David J. , White Harvey D. , Van de Werf Frans , Harrington Robert A. , Wallentin Lars , Held Claes , Armstrong Paul W. , Aylward Philip E. , Strony John , Mahaffey Kenneth W. , Gibson C. Michael 
Published: May 2016

Background—
Stent thrombosis (ST) is an important end point in cardiovascular clinical trials. Adjudication is traditionally based on clinical event committee (CEC) review of case report forms and source documentation rather than angiograms. However, the degree to which this method of adjudication is concordant with the review of independent angiographic core laboratories (ACLs) has not been studied. This report represents the first assessment of variability between local investigators (LIs), a CEC, and an ACL.

Methods and Results—

Serial angiograms of 329 patients with acute coronary syndrome without ST-segment–elevation who underwent percutaneous coronary intervention at entry in the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRACER) and who met criteria for possible ST subsequent to the index event were reviewed by an ACL. The ACL was blinded to the assessment by both LIs and the CEC regarding the presence or absence of ST. CEC adjudication was based on Academic Research Consortium definitions of ST, using case report form data and source documents, including catheterization laboratory reports. The ACL, CEC, and LIs agreed on the presence or absence of ST in 52.9% events (
κ
=0.32; 95% confidence interval, 0.26–0.39). The ACL and CEC agreed on 82.7% of events (
κ
=0.57; 95% confidence interval, 0.47–0.67); the ACL and LIs agreed on 61.1% of events (
κ
=0.25; 95% confidence interval, 0.16–0.34); and the CEC and LIs agreed on 62% of events (
κ
=0.28; 95% confidence interval, 0.21–0.36).

Conclusions—
ST reporting by an ACL, a CEC, and LIs is discordant. The assessment of ST is more often detected by direct review of angiograms by an ACL.

Clinical Trial Registration—

URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00527943.
Is There a Relationship of Operator and Center Volume With Access Site–Related Outcomes?
Authors: Hulme William , Sperrin Matthew , Rushton Helen , Ludman Peter F. , De Belder Mark , Curzen Nick , Kinnaird Tim , Kwok Chun Shing , Buchan Iain , Nolan James , Mamas Mamas A. 
Published: May 2016

Background—
Transradial access is associated with reduced access site–related bleeding complications and mortality post percutaneous coronary intervention. The objective of this study is to examine the relationship between access site practice and clinical outcomes and how this may be influenced by operator and center experience/expertise.

Methods and Results—

The influence of operator and center experience/expertise was studied on 30-day mortality, in-hospital major adverse cardiovascular events (a composite of in-hospital mortality and in-hospital myocardial infarction and target vessel revascularization) and in-hospital major bleeding based on access site adopted (radial versus femoral). Operator/center experience/expertise were defined by both total volume and transradial access proportion. A total of 164 395 procedures between 2012 and 2013 in the National Health Service in England and Wales were analyzed. After case-mix adjustment, transradial access was associated with an average odds reduction of 39% for 30-day mortality compared with transfemoral access (odds ratio, 0.61; 95% confidence interval, 0.55–0.68;
P
<0.001). The magnitude of this risk reduction was modified by increases in total procedural volume and radial proportion at the operator level (odds ratio reduction of 11% per 100 extra procedures, 95% confidence interval, 3%–19%; odds ratio reduction of 6% per 10%-point increase in radial proportion, 95% confidence interval, 1%–11%) with no significant impact of operator radial volume, center total volume, center radial volume, and center radial proportion.

Conclusions—
The lower mortality associated with transradial access adoption relates to both the total procedural volume and the proportion of procedures undertaken radially by operator, with operators undertaking the greatest proportion of their procedures radially having the largest relative reduction in mortality risk.
Percutaneous Transluminal Angioplasty in Patients With Infrapopliteal Arterial Disease
Authors: Mustapha J.A. , Finton Sara M. , Diaz-Sandoval Larry J. , Saab Fadi A. , Miller Larry E. 
Published: May 2016

Background—
Contemporary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopliteal atherosclerotic lesions are not well characterized. Hence, a systematic review and meta-analysis was performed to determine the safety and effectiveness of this approach in patients with advanced below-the-knee arterial disease.

Methods and Results—
MEDLINE and EMBASE databases were searched for contemporary studies (2005–2015) on the effects of percutaneous transluminal angioplasty for the treatment of infrapopliteal lesions. A random effects meta-analysis model was used to analyze procedural (technical success, flow-limiting dissection, provisional stent placement) and long-term (primary patency, repeat revascularization, major amputation, all-cause mortality) outcomes. Ultimately, 52 studies encompassing 6769 patients with 9399 below-the-knee lesions were included in the analysis. Technical success was 91.1% (95% confidence interval [CI], 88.8–93.0), and the incidence of flow-limiting dissections and bailout stenting was 5.6% (95% CI, 3.2–9.8) and 9.1% (95% CI, 6.3–12.9), respectively. Outcomes at 1 year were primary patency, 63.1% (95% CI, 57.3–68.6); repeat revascularization, 18.2% (95% CI, 14.5–22.6); major amputation, 14.9% (95% CI, 12.3–18.0); and all-cause mortality, 15.1% (95% CI, 12.8–17.7). Significant heterogeneity and publication bias were observed for most percutaneous transluminal angioplasty outcomes.

Conclusions—
Contemporary studies of the use of percutaneous transluminal angioplasty as primary treatment for patients with infrapopliteal arterial disease reveal suboptimal procedural and 1-year clinical outcomes.
Culprit Vessel Revascularization Prior to Diagnostic Angiography as a Strategy to Reduce Delays in Primary Percutaneous Coronary Intervention
Authors: Couture Etienne L. , Bérubé Simon , Dalery Karl , Gervais André , Harvey Richard , Nguyen Michel , Parenteau Émilie , Daneault Benoit 
Published: May 2016

Background—
Delays are important markers of quality of care in primary percutaneous coronary intervention. There is scarce data on the impact of obtaining a complete diagnostic angiography before primary percutaneous coronary intervention.

Methods and Results—
Consecutive patients treated with primary percutaneous coronary intervention at our institution between January 2012 and December 2014 were studied. After excluding patients with prior coronary artery bypass surgery, 925 patients were included in the analysis. Patients were classified into 3 groups according to the as-treated revascularization strategy: culprit-vessel revascularization first, contralateral angiography first, or complete angiography first. Propensity score matching was used to minimize difference in clinical characteristics between groups. Predictors of culprit-vessel first revascularization were anterior/lateral infarct location and absence of diabetes mellitus. After propensity score matching, the median vascular access-to-balloon time was 4 to 6 minutes shorter with a culprit-vessel revascularization first strategy. This reduction in time to reperfusion increased the proportion of patients treated within recommended delays. However, there was no significant difference in 30-day clinical outcomes associated with these delays reduction.

Conclusions—
Performing culprit-vessel primary percutaneous coronary intervention before contralateral or complete diagnostic angiography is associated with a statistically significant reduction in vascular access-to-balloon time, although the 4- to 6-minute difference is unlikely to be clinically relevant. This small but significant reduction could translate in an augmentation in the proportion of patients treated within recommended delays.
Impact of Nurse-Led, Multidisciplinary Home-Based Intervention on Event-Free Survival Across the Spectrum of Chronic Heart Disease
Authors: Stewart Simon , Wiley Joshua F. , Ball Jocasta , Chan Yih-Kai , Ahamed Yasmin , Thompson David R. , Carrington Melinda J. 
Published: May 2016

Background—
We sought to determine the overall impact of a nurse-led, multidisciplinary home-based intervention (HBI) adapted to hospitalized patients with chronic forms of heart disease of varying types.

Methods and Results—

Prospectively planned, combined, secondary analysis of 3 randomized trials (1226 patients) of HBI were compared with standard management. Hospitalized patients presenting with heart disease but not heart failure, atrial fibrillation but not heart failure, and heart failure, as well, were recruited. Overall, 612 and 614 patients, respectively, were allocated to a home visit 7 to 14 days postdischarge by a cardiac nurse with follow-up and multidisciplinary support according to clinical need or standard management. The primary outcome of days-alive and out-of-hospital was examined on an intention-to-treat basis. During 1371 days (interquartile range, 1112–1605) of follow-up, 218 patients died and 17 917 days of hospital stay were recorded. In comparison with standard management, HBI patients achieved significantly prolonged event-free survival (90.1% [95% confidence interval, 88.2–92.0] versus 87.2% [95% confidence interval, 85.1–89.3] days-alive and out-of-hospital;
P
=0.020). This reflected less all-cause mortality (adjusted hazard ratio, 0.67; 95% confidence interval, 0.50–0.88;
P
=0.005) and unplanned hospital stay (median, 0.22 [interquartile range, 0–1.3] versus 0.36 [0–2.1] days/100 days follow-up;
P
=0.011). Analyses of the differential impact of HBI on all-cause mortality showed significant interactions (characterized by U-shaped relationships) with age (
P
=0.005) and comorbidity (
P
=0.041); HBI was most effective for those aged 60 to 82 years (59%–65% of individual trial cohorts) and with a Charlson Comorbidity Index Score of 5 to 8 (36%–61%).

Conclusions—
These data provide further support for the application of postdischarge HBI across the full spectrum of patients being hospitalized for chronic forms of heart disease.

Clinical Trial Registration—

URL:
http://www.anzctr.org.au
. Unique identifiers: 12610000221055, 12608000022369, 12607000069459.